Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Zymeworks Inc

(TSX: ZYME.TO)
Add to Portfolio
+0.15 (+0.45%)
as of 12:33 EDT

Last 33.84
Change +0.15 (+0.45%)
Open 33.72
Prev. Close 33.69
Today's Range
33.26
33.84
52wk Range
14.34
39.10
Volume 2,337
Avg Volume 7,490

Perfomance Comparison

Name Today 3-Month 1-Year
ZYME.TO +0.45% +5.35% +80.48%
$TXCX -0.17% +2.02% +3.70%
$TXSC -0.09% +2.04% +4.69%
DJIA -0.18% +0.91% +2.97%
S&P 500 -0.27% +0.45% +3.06%

Key Statistics

Annual EPS -1.55
Dividend Yield N/A
P/E Ratio N/A
Market Capitalization, $K 1,322,667
Weighted Alpha +71.40
Standard Deviation +0.14
Profit Margin -1.03%
Beta N/A

Growth Rates

YTD +69.88%
1-Year +58.02%

Opinion

Sell Hold Buy

Recent Headlines

Zymeworks Announces Election of Directors and Voting

BusinessWire via COMTEX - Fri May 03, 06:45AM EDT
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce the detailed voting results on the items of business considered at(full story)
ZYME: 25.50 (-0.08), ZYME.TO: 33.84 (+0.15)

Zymeworks Reports 2019 First Quarter Financial Results

BusinessWire via COMTEX - Thu May 02, 05:00PM EDT
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the first quarter ended March 31, 2019.(full story)
ZYME: 25.50 (-0.08), ZYME.TO: 33.84 (+0.15)

Zymeworks Adds Experienced Executives to Management

BusinessWire via COMTEX - Tue Apr 30, 06:45AM EDT
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced it has expanded its leadership team with the hiring of three new vice pre(full story)
ZYME: 25.50 (-0.08), ZYME.TO: 33.84 (+0.15)

Daiichi Sankyo Selects Lead Candidate Built on

BusinessWire via COMTEX - Thu Apr 25, 06:45AM EDT
--Zymeworks to receive US$3.5 million commercial license payment from Daiichi Sankyo(full story)
ZYME: 25.50 (-0.08), ZYME.TO: 33.84 (+0.15)

Zymeworks Opens Phase 2 Clinical Trial for ZW25 in

BusinessWire via COMTEX - Mon Apr 15, 06:45AM EDT
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced it has initiated its global multicenter Phase 2 clinical trial evaluating ZW25 (full story)
ZYME: 25.50 (-0.08), ZYME.TO: 33.84 (+0.15)